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The synthesis and conformational analysis of -caprolactams containing a –COOMe group at 
the C-6 position is described. The influence of different C-2, C-6 and N substituents on ring 
conformation was studied using X-ray crystallography and NMR spectroscopy. The results 
provide evidence that all the analysed caprolactams adopt a chair type conformation with a 
planar lactam. In the 6-substituted caprolactam, the –COOMe residue prefers to reside in an 
equatorial position, but can be induced to occupy an axial orientation by the introduction of a 
bulky tert-butyloxycarbonyl (BOC) group on the lactam nitrogen or by C-2/C-3 ring 
desaturation. The BOC protected caprolactam was found to undergo exchange between two 
chair forms as detected by solution NMR, one with the C-6 ester equatorial (30 %) and the 
other with it in the axial position (70 %); the latter was observed by X-ray crystallography. 
For the C-2 dithiocarbamate substituted C-6 methyl ester seven-membered rings, a single 
chair form is observed for cis-isomers with both substituents equatorial. The analogous trans- 
isomers, however, exist as two chair forms in a 1:1 equilibrium ratio of 
1,N
C4 and 
4
C1,N 
conformers, where either substituent can occupy axial or equatorial positions.  
  
Introduction 
 
-Caprolactam, or hexahydro-2-azepinone, is an important starting material in polymer 
chemistry; it is produced from cyclohexanone by Beckmann rearrangement.
1
 -Caprolactam is 
used in nylon preparation,
2
 and as such is the basis for the manufacturing of many useful 
products. Derivatives of -caprolactam are of interest for the production of modified nylons3 
and nanogels
4
. Azepinones and their unsaturated and  saturated analogues play an important 
role in medicinal chemistry,
5
 including in drugs (e.g. Benazepril,
6
 Ivabradine,
7
 Telcagepant
8
), 
antibiotic research (e.g. capuramycin
9
), and  as simple models of cyclic peptides.
10
 Despite the 
importance of caprolactams, reports on the influence of substituents on the conformations of 
caprolactam rings and the mutual influence of different substituents are rare
11
 including with 
respect to the solid state behavior of single component caprolactams and respective co-
crystals.
12
  
     Although the influence of various substituents on the conformation of cyclohexanes has 
been studied in detail, analogous reports on seven-membered rings are much less 
comprehensive. Based on studies of the conformation at the cycloheptene ring,
13
 caprolactams 
are predicted to exist in (pseudo) ‘chair’, ‘boat’ or a transition ‘twisted boat’ or ‘twisted chair’ 
conformations. In the case of the ‘chair ‘form, two energetically favoured chair conformations 
can be identified (
4
C1,N and 
1,N
C4), assuming the amide C-C(=O)-N-C segment is planar
14
 
(Scheme 1). Furthermore it is known, that axial substituents on caprolactams are higher in 
energy than the equatorial substituents as shown for methyl and tert-butyl substituents at C-2 
and C-6.
15
  
 
 
 
Scheme 1     The two energetically favoured (pseudo) chair conformations of -caprolactam: 
1,N
C4 and 
4
C1,N. (For consistency we apply here the reported numbering system.
14
)  
 
 
     Arising from studies on -lactam antibiotic biosynthesis and mode of action,16 we were 
interested in a caprolactam functionalized at C-6 with a –COOMe group (1). For subsequent 
reactions concerning the caprolactam core we were keen to alter the conformation of the ring 
and position the methyl ester in an axial position. For this purpose, the effects of a C-2 
substituent (adjacent to the rigid amide) and at the amide nitrogen on the conformations of the 
respective caprolactam derivatives were tested. Here we report solution NMR and 
crystallographic structural studies on the effects of substituents on caprolactam conformation. 
 
 
Results and Discussion 
 
Synthesis 
 
For the preparation of methyl ester 1 we investigated several different reactions. In 
contrast to the efficient - and -lactam preparation, analogous cyclization of the respective 
racemic aminopimelic acid with subsequent methylation had little success when using 
activating agents such as 3,4,5-trifluorobenzene boronic acid
17
 (no reaction) or SiO2
18
 (10 % 
yield). However, preparation of the dimethyl ester of aminopimelic acid followed by heating 
in refluxing p-cymene
19,20
 gave 1 in reasonable yield (57%, unoptimised). The free 
caprolactam acid 2 was obtained after saponification of 1 (LiOH, aq. THF) (70 %). 
In order to introduce a sterically hindered tert-butyloxycarbonyl group at the amide 
nitrogen, 1 was reacted with (
t
BuOCO)2O under basic conditions in toluene to give 3. For C-2 
substitution, we first carried out bromination using molecular bromine
21
 to yield an 
inseparable mixture of isomers (4). Subsequent treatment with two different dithiocarbamate 
salts yielded compounds 5 and 6, which could be separated into cis and trans isomers, with a 
significantly higher amount of the cis isomer being formed. (The dithiocarbamates were 
chosen as, in general, they allow versatile consecutive reactions.
22
 After a Tschugaev-like 
pyrolysis,
23
 we obtained the C-2/C-3 unsaturated caprolactam (7), together with the 
rearranged C3/C4 isomer (8) in a 1:1 ratio
24
 (Scheme 2). 
 
 
Scheme 2     Synthesis of caprolactam derivatives 1-8.  
Conformational analyses of monosubstituted caprolactams  
 
Caprolactam derivatives 1, 2, 3, 5 cis, 5 trans and 6 cis and 7 were characterized by 
single-crystal X-ray diffraction. For selected crystallographic and structural refinement 
parameters, molecular torsion angles, and information regarding hydrogen bond geometries 
see Tables 1, 2 and S1. The molecular overlay calculation data, rmsd (= root mean square of 
the atomic distances) and maxd (the maximal atomic distance difference of corresponding 
atoms) for the caprolactam moieties with respect to -caprolactam are listed in Table 3. 
Crystal structures of -caprolactam have been reported;25,26 the most recently reported 
structure of caprolactam (published by Winkler and Dunitz in 1975), was used for comparison 
as it has the best reported agreement factors (Cambridge Structural Database REFCODE: 
CAPLAC).  
 
 
a) 
 
 
 
b) 
 
c) 
 
  
Fig. 1     a) Caprolactam 1 in its two chair forms. 
4
C1,N is 8 kcal/mol higher in energy than 
1,N
C4 as calculated by molecular modelling using MacroModel. b) Displacement ellipsoid plot 
of 1 from single crystal diffraction data and c) dimer formation in 1 showing the  
hydrogen bonding motif.  
 
)8(22R
Table 1     Crystallographic and structure refinement data of the compounds studied. 
Compound 1 2 3 5 cis 5 trans 6 cis 7 
Empirical formula C8H13NO3    C7H11N1O3  C13H21NO5    C11H18N2O3S2 C11H18N2O3S2 C13H20N2O3S2 C8H11NO3    
Formula weight (g mol-1) 171.19 157.17  271.31 290.40 290.40 316.44 169.18 
Crystal system triclinic triclinic monoclinic monoclinic triclinic monoclinic triclinic 
Space group P-1 P-1 P21/n P21/c P-1 P21/n P-1 
     a (Å) 5.2735(2) 10.5713(8) 6.27304(11) 7.54965(8) 7.9432(6) 7.71325(7) 6.2079(4) 
     b (Å) 8.6164(4) 10.6265(5) 8.13334(11) 7.8511(1) 8.4258(6) 8.16076(7) 7.7139(7) 
     c (Å) 9.3766(4) 11.0705(7) 27.2810(5) 23.3724(3) 11.2990(8) 23.7540(2) 8.6278(8) 
     °) 97.6974(18) 72.339(5) 90 90 89.703(6) 90 82.686(8) 
     °) 93.5064(18) 78.005(6) 91.0045(16) 95.6507(11) 71.855(6) 94.6857(8) 88.718(7) 
     °)  95.8677(19) 80.552(5) 90 90 73.959(6) 90 89.279(6) 
     V (Å3) 418.80(3) 1152.29(13) 1391.68(4) 1378.62(3) 687.92(9) 1490.22(2) 409.68(6) 
     Z  2 6 4 4 2 4 2 
Dc (Mg m
-3) 1.358 1.359 1.295 1.399 1.402 1.410 1.371 
mm-1) 0.104 0.896 0.826 3.539 0.389 3.323 0.884 
Data collection        
     Temperature (K) 150 150 150 150 150 150 150 
     Wavelength (Å) 0.71073 1.54184 1.54184 1.54184 0.71073 1.54180 1.54184 
     No. of collected reflections 7659 10066 13198 11617 6132 19616 3072 
     max (°)
 27.408 76.407 76.124 76.330 30.707 76.356 75.764 
     Completeness to max (%) 98.6 98.1 95.6 99.0 83.0 99.3 97.3 
     No. of unique reflections 1882 4752 2770 2866 3550 3107 1671 
     R(int) 0.028 0.023 0.028 0.025 0.037 0.021 0.011 
No. of refined parameters 109 298 172 163 163 181 109 
No. Reflections [I>2(I)] 918 3278 2364 2866 2530 2987 1592 
     Final R-Indices        
R1 [I>2(I)] (%) 4.24 5.83 3.49 2.77 5.65 2.57 3.27  
wR [I>2(I)] (%) 10.79 15.18 8.54 7.18 9.53 10.49 8.83 
S (=Goodness of fit on F2) 0.9467 0.9925 0.9877 0.9588 1.0097 0.9997 1.0124 
     Final max/min (e Å
-3) 0.28,-0.28 1.03,-0.32 0.33,-0.23 0.30,-0.21 0.66,-0.67 0.29,-0.21 0.23,-0.18  
a P = (Fo
2 + 2Fc
2)/3. 
Table 2     Torsion angles (°) for ring atoms in the caprolactam structures 
 
 
Atoms  1 2(1) 2(2) 2(3) 3 5 cis 5 trans 6 cis 7 
           
C1-C2-C3-C4  82.8(3) -80.8(3) -79.3(3) 81.7(3) 84.34(17) 83.88(12) -84.3(3) 84.96(10) -2.1(2) 
C2-C3-C4-C5  -61.4(3) 64.7(4) 59.4(3) -64.1(4) -60.79(17) -67.42(14) 67.6(3) -67.75(12) 1.29(18) 
C3-C4-C5-C6  59.3(3) -62.0(4) -61.6(3) 61.9(3) 60.03(17) 63.95(15) -60.0(3) 63.48(12) -44.53(15) 
C4-C5-C6-N1  -77.3(3) 75.9(3) 81.4(2) -77.2(3) -79.65(16) -75.49(14) 69.1(3) -75.44(12) 80.94(14) 
C1-N1-C6-C5  66.5(3) -66.1(3) -65.1(3) 66.2(4) 65.01(15) 62.76(16) -63.2(4) 62.63(14) -54.82(15) 
C6-N1-C1-C2  -0.4(3) 5.0(4) -4.8(3) -2.5(4) -0.49(16) 0.93(18) 5.2(4) 1.65(15) -2.02(15) 
N1-C1-C2-C3  -68.0(3) 61.5(3) 70.3(3) -63.9(4) -67.95(16) -66.95(14) 62.5(3) -67.75(11) 25.22(18) 
N1-C6-C7-O2  -7.3(3) 5.9(3) 0.3(3) 4.4(4) 14.50(16) -11.24(14) -9.6(4) -10.46(14) 15.92(15) 
           
 
General numbering scheme for compound 3: 
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Fig. 2     The pseudo threefold symmetry of the three crystallographic independent molecules 
in the asymmetric unit of 2 (a) and the structures of caprolactam acid 2 (only one molecule of 
the asymmetric unit is displayed for clarity) (b), the desaturated lactam 7 (c), the N-
functionalized lactam 3 (d) and the dithiocarabmates 5 cis (e), 6 cis (f) and 5 trans (g) from 
single crystal diffraction studies. Displacement ellipsoids are drawn at the 50% probability 
level and hydrogen atoms (except those illustrating hydrogen bonding interactions) are 
omitted for clarity. 
 
 
 
Generally in monosubstituted caprolactams, axial substituents are anticipated to be higher 
in energy than the equatorial ones, a conclusion supported by molecular mechanics 
calculations carried out on the C6 methyl ester (1). The 
4
C1,N form with the carboxylate in the 
axial position is calculated to be 8 kcal/mol higher in energy than the 
1,N
C4 with the methyl 
ester in the equatorial position (Fig. 1a). Indeed, the predicted lower energy form is observed 
in our crystal structure of 1 (Fig. 1b) which reveals the –COOMe moiety in an equatorial 
position and with the ester carbonyl group (N1-C6-C7-O2) being almost coplanar with respect 
to the amide (C6-N1-C1-C2) (Table 2). In the packing of 1, two molecules form hydrogen-
bonded dimers via N-H∙∙∙O hydrogen bonds [d(N∙∙∙O) = 3.056(3) Å] (Fig. 1c). The graph set 
descriptor is )8(
2
2R , which is also seen in the -caprolactam (CAPLAC)
26
 and the C-2/C-6 
dimethyl
27
 and C-2 phosphinoxide derivatives.
28
  
 
In contrast to 1, in the solid state, caprolactam acid 2 has three crystallographically 
independent molecules in the asymmetric unit; these form a trimer arranged around an 
approximate non- crystallographic three fold axis.  The molecules are connected via three sets 
of strong NH∙∙∙O and OH∙∙∙O contacts [d(N∙∙∙O) = 2.970(4) - 3.074(4) Å; d(O∙∙∙O) = 2.543(4) - 
2.555(4) Å] from the )8(
2
2R -type (Table S1, Fig. 2a). Careful examination of the three 
crystallographically unique molecules in 2 shows they have two different configurations at the 
chiral C6. Although this gives a ratio of 2:1 within the asymmetric unit, as the space group is 
centrosymmetric, the overall crystal is racemic,
29
 i.e. the final ratio of the two (S) and (R) 
forms on C6 of the molecules is 1:1. Converting the three crystallographically independent 
molecules to the same configuration (i.e. inverting one) demonstrates that their molecular 
geometries are very similar. Hence, the loss of the methyl ester from 1 to 2, does not 
substantially influence the conformation (Table 2). The carboxylic acid function of 2 is in the 
equatorial position as observed for the -COOMe ester in 1 (Fig. 2b). 
 
The introduction of a double bond between C2 and C3 of caprolactam ester 1 as in 7 
“flattens” the seven membered ring chair conformation (Table 2, Fig. 2c). However, the 
carbonyl group and the double bond are not fully coplanar, with a dihedral angle of 22.49(7)°. 
Notably, the placement of the -COOMe substituent on C6 has a different influence on the 
saturated and unsaturated compounds respectively i.e. it switches from an equatorial to an 
axial position, however, the dimer formation via )8(
2
2R hydrogen bonds [d(N∙∙∙O) = 
2.8618(16) Å] of 7 is observed again. 
 
 
 
Conformational analyses of disubstituted caprolactams 
 
 
Crystallographic Studies  
 
On N-substitution at the amide of 1 with the tert-butyloxycarbonyl (BOC) group to give 
3, the caprolactam ring conformation is slightly changed (Table 2, Fig. 2d). The carbonyl 
groups of -COOMe at C-6 and the -COOC(CH3)3 at N-1 are trans relative to each other, with 
the BOC carbonyl being approximately coplanar with the amide segment (C1-N1-C9-O4 = 
8.38(17)°). Presumably due to the steric demand of the BOC group, the C-6 ester (which is in 
the equatorial position in the structures previously described), preferentially adopts the 
normally energetically disfavoured, axial position. As the amide proton is missing, no 
intramolecular dimer formation is observed. Instead, C6-H61···O2 weak intermolecular 
contacts apparently enable dimeric interactions. 
 
The disubstituted lactams 5 and 6 were obtained as pairs of cis/trans-diastereomers. We 
were able to grow single crystals from the cis isomers of both 5 and 6 and the trans isomer of 
5. Atoms C-2 and C-6 of the cis-dithiocarbamates (5, 6) have the same configuration and 
crystallise in centrosymmetric space groups (making them racemic). In each case, both 
substituents adopt equatorial positions and neither the presence of the more flexible dimethyl 
group nor the preorganized pyrroldine dithiocarbamate group substantially influence the 
caprolactam ring conformation (Table 2, Fig. 2e, f). The C2 substituent of 6 does not have a 
significant effect on the ring conformation as shown by the low cell similarity index ()30 of 
0.03324 for 5 and 6. Superimposing all 18 heavy atoms of 5 with the corresponding atoms of 
6, the root mean square of the atomic distances rmsd = 0.008, the largest atomic distance 
difference of corresponding atoms maxd = 0.014, which is lowest for all structures compared 
herein (Table 3).  
 
 
Table 3     Overlay of the caprolactam moiety 
(e.g. N1, O1, C1, C2, C3, C4, C5 and C6) of 
 the investigated structures. "rmsD": root mean 
 square of the atomic distances, "maxD": the 
 largest atomic distance difference of  
corresponding atoms. 
 
Compared structures rmsD maxD 
    
CAPLAC 1 0.0391 0.0668 
1 2(1)* 0.0856 0.1817 
1 2(2) 0.0925 0.1907 
1 2(3)* 0.0626 0.1150 
1 3 0.0429 0.0786 
1 5 cis 0.0302 0.0489 
1 6 cis* 0.0290 0.0437 
1 7* 0.2273 0.4423 
2(1)* 2(2) 0.0734 0.1227 
2(1)* 2(3)* 0.1223 0.2196 
2(2) 2(3)* 0.0894 0.2149 
5 cis 6 cis* 0.0084 0.0136 
    
 
* Structure is inverted related to the received one or 
related to the other molecule present in the asymmetric unit. 
 
 
 
In contrast to the literature structure of caprolactam,
25,26
 and the structures of 1 and 7 
herein, no stereotypical N-H∙∙∙O amide dimers are seen for the cis diastereoisomers of the 
dithiocarbamate derivatives 5 and 6 in the crystalline state. This is interesting because the N-
H of the amide of 5 and 6 do not form any hydrogen bonds at all. The strong N-H∙∙∙O 
hydrogen bonds are apparently replaced by weaker C-H···O interactions to the amide oxygen 
O1 and short contacts between the ester oxygen and the dithiocarbamate.It is possible that, C-
H···S,
31
 N-H···S
32
 and S···S
33
 contacts are relevant (Fig. S1).  
In the trans-diastereomer of 5 the chair is again the favoured conformation of the 
caprolactam core with one substituent adopting an axial orientation (C6) whilst the other (C-
2) adopting an equatorial position (Fig. 2g). Likely for steric reasons, the C-2 dithiocarbamate 
residue is in the equatorial position forcing the C-6 methyl ester into the axial position. 
Consequently, this leads to a rather short intermolecular distance of 2.424(3) Å between the 
carbonyl of the methyl ester and the facing methylene hydrogen. In the packing of 5 trans, 
amide dimers featuring the )8(
2
2R  motif are the most striking feature (Table 4). 
 
 
Table 4     Influence of one and two substituents on their relative position on the ring and the 
CO∙∙∙NH bonding pattern in the solid state of the caprolactams investigated 
 
 C(6) substituent 2
nd
 substituent 
H bonding  
Pattern
34
  
      
CAPLAC - - - -  
1 -COOMe equatorial - -  
2 -COOMe equatorial - -  
3 -COOMe axial N-BOC 
lactam and N-BOC 
carbonyls coplanar 
- 
5 cis -COOMe equatorial C2-S(S)C-N(Me)2 equatorial - 
5 trans -COOMe axial C2-S(S)C-N(Me)2 equatorial  
6 cis -COOMe equatorial C2-S(S)C-N(CH2)4 equatorial - 
7 -COOMe axial - -  
      
 
 
 
NMR Solution Studies  
 
To investigate the influence of a substitution on caprolactam conformation in solution, NMR 
studies were carried out initially on the N-BOC protected C-6 substituted methyl ester 3 at 
different temperatures (183-298 K) in CD2Cl2 (Fig. 3). The 
1
H NMR spectrum of 3 was sharp 
and well resolved at 298 K, but exhibited broadening as the temperature was lowered, 
suggesting dynamic conformational exchange. At 183 K, the signals were too broad to obtain 
meaningful J-coupling or NOE information. 
 
)8(22R
)8(22R
)8(22R
)8(22R
)8(22R
 
 
Fig. 3     
1
H NMR spectra of the N-Boc protected C-6 substituted methyl ester (3) at different 
temperatures (183-298 K) in CD2Cl2. 
 
 
NOE experiments on 3 at room temperature, however, were consistent with both 
1,N
C4 and 
4
C1,N  forms being present in solution due to the presence of a medium strength NOE between 
the methyl ester and H2’ in 4C1,N and strong-medium NOEs between H6 and H2 and H6 and 
H4 in 
1,N
C4. These two groups of mutually exclusive NOEs can only be observed if the two 
chair forms 
1,N
C4 and 
4
C1,N are present in fast exchange (Fig. 4a) at room temperature. 
 
 
 
 
 
 
 
 
 
temp = 263 K 
temp = 298 K 
temp = 193 K 
temp = 183 K 
 
 
Fig. 4     Conformational isomers of the caprolactams 3 (a), 5 cis, 6 cis (b), 5 trans and 6 trans 
(c). Within caprolactam 3 and trans dithiocarbamates 5 and 6, 
1,N
C4 and 
4
C1,N are in fast 
conformational exchange at room temperature in either CD2Cl2 or C6D6. Observed NOEs, 
indicated by dotted red arrows, are consistent with both forms being present in solution 
(spectral overlap for H4’ negated its irradiation in either CD2Cl2 or C6D6). 
 
Conformational averaging is also reflected in the vicinal J-couplings at room tempterature, for 
example 
3
J(H6,H5) = 6.3 Hz, 
3
J(H6,H5’) = 3.0 Hz (values for 3J(Hax,Hax) = ~11.0 Hz, 
3
J(Hax,Heq) = 2-5 Hz and 
3
J(HeqHeq) = 2-4 Hz
35
 in conformationally ‘frozen’ forms; see later 
section on cis-isomer of dithiocarbamates 5 and 6). Assuming for 3 the existence of the two 
chair conformers in dynamic exchange at room temperature, it is possible to calculate the 
conformer populations of 
1,N
C4 and 
4
C1,N from the averaged vicinal coupling constants
36,37 
and 
the literature values of 
3
J couplings in conformers with distinct conformations in similar 
systems.
38
 For the BOC protected methylester 3, a ratio of 70 : 30 was calculated with the 
higher populated chair form having the ester substituent in an axial position, thus minimising 
the steric bulk of the BOC group; the latter is as observed in the X-ray structure, see Fig. 2d. 
The NMR observations are consistent with the molecular dynamics calculations, where 
simulations commencing with the equatorial methyl ester 
1,N
C4,  proceed to yield twisted 
chairs, boat and finally the more stable axial methyl ester 
4
C1,N conformation (by energy 
difference ~8 kcal/mol in favour of 
4
C1,N). The less populated conformer of 3 is less favoured 
energetically due to steric clash between the equatorial ester function being in close proximity 
to the BOC substituent.  
 
The NMR results for cis isomers of dithiocarbamates 5 and 6 are apparently unambiguous and 
irrespective of solvent (e.g. CD2Cl2 or C6D6). The proton resonances are sharp indicating a 
predominant conformer with both J-couplings and the NOEs consistent with a chair 
4
C1,N  
species containing both 6- and 2- substituents in equatorial positions, see Fig. 4b below. The 
solution analyses are thus consistent with both X-ray structures. An unusual feature of the 
spectra for 5 and 6 (both cis) is the low coupling constant for 
3
J(H2,H3) which approaches 
zero (1.0-1.8 Hz), see Table 5, suggesting a close to 90
o
 dihedral angle for H2ax-C2-C3-H3eq 
this angle is 79
o
 in the X-ray structure and the energy minimised structure predicts an angle of 
81
o
, also consistent with the observed vicinal coupling constant. The other vicinal coupling 
constant for the corresponding protons on the other side of the seven-membered ring, 
3
J(H6,H5) is ‘normal’ for 3J(Hax,Heq) of 4.5-5.2 Hz corresponding to a smaller dihedral angle; 
in this case the X-ray structure reveals this angle is 68.5
o
 as does the calculated value. An 
explanation for the unusual small coupling constant for 
3
J(H2ax,H3eq) and 80
o 
dihedral angle 
may reside in the bulky partially delocalised dithiocarbamate group, sterically forcing the 
dihedral angle containing the equatorial proton H3, to twist in order to accommodate it.  
 
The flipping of the ring of the 
4
C1,N to the 
1,N
C4 chair of 5 cis and 6 cis would mean both C-2 
and C-6 substituents are in the axial position, which is not favoured energetically. Molecular 
dynamics simulations suggest the energy difference between the favoured di-equatorial 
4
C1,N  
species and the di-axial 
1,N
C4 conformation is ~20 kcal/mol, which is presumably why the 
later form is not observed in solution by NMR. 
 
In the case of the trans dithiocarbamates caprolactams trans-5 and trans-6, the NMR studies 
reveal that at room temperature there is fast conformational exchange between the two chair 
forms, 
1,N
C4 and 
4
C1,N, irrespective of the type of dithiocarbamate substituent. The 
3
J(H2,H3), 
3
J(H2,H3’), 3J(H6,H5) and 3J(H6,H5’) values (Table 4) represent conformationally averaged 
ensembles of the two forms, although the conformer distribution may be more biased towards 
4
C1,N in C6D6 since 
3
J(H2,H3’) tends towards values for axial H2 compared to CD2Cl2 
solutions (compare 
3
J(H2,H3’) of 9.8 to 10Hz in C6D6 versus 8.0 to 8.3Hz in CD2Cl2). The 
observed NOEs are also consistent with both forms being present from the NOEs between H2 
and the Me ester (
4
C1,N) and H6 and the dithiocarbamate NMe or NCH2 substituent (
1,N
C4). In 
this situation, where either substituent can occupy an axial orientation, the steric clash 
between them is minimised. The energy differences between 
1,N
C4 and 
4
C1,N conformers is 
predicted to be low 5-8 kcal/mol in favour of 
4
C1,N, unlike the cis isomer, where only one 
species is observed in solution.  
 
Table 5      
Observed 
3
J-coupling constants (
3
JH,H in Hz)  
for caprolactams 3, 5 and 6 
 
Coupling atoms CD2Cl2 C6D6 
     
3* 298 K 298 K 
H2-H3 7.0 - 
H2-H3’ 2.7 - 
H6-H5 6.3 - 
H6-H5’ 3.2 - 
     
5 (cis)     
H2-H3’ 11.6 11.4 
H2-H3 < 1.0 1.7 
H6-H5 10.8 10.8 
H6-H5’ 5.2 4.9 
     
6 (cis)     
H2-H3’ 11.4 11.2 
H2-H3 1.8 1.8 
H6-H5’ 10.9 11.0 
H6-H5 4.5 5.2 
     
5 (trans) 298 K 229 K 298 K* 
 ** 
1,N
C4 
4
C1,N    
H2-H3’ 8.3 10.5 # 9.8 
H2-H3 2.5 0 # 2.0 
H6-H5 5.9 # 10.4 * 
H6-H5’ 2.9 # # * 
     
6 (trans) 298 K** 198 K 298 K* 
  
1,N
C4 
4
C1,N    
H2-H3’ 8.0 10.2 # 10.1 
H2-H3 2.5 0 # 2.0 
H6-H5 7.0 # 10.8 * 
H6-H5’ 2.4 # 3.9 * 
     
 
*
Signals broadened by dynamic conformational averaging 
**
 sharp signal, fast conformational exchange 
#
 J-coupling indiscernible due to line broadening from  
  conformational exchange or signal overlap 
 
 
For trans 5 and 6, at 198 K - 229K in CD2Cl2, both 
4
C1,N and 
1,N
C4  forms are clearly observed 
in the proton spectra, in a ratio of 1: 0.9, a slight excess of 
4
C1,N. The NOESY spectrum of 5 
trans (Fig. 5), reveals conformational exchange is evident even at 198 K, as shown from the 
exchange cross peaks which are of opposite phase to those of the NOEs. The NOEs, however, 
were also consistent with both 
4
C1,N and 
1,N
C4 forms present in dynamic exchange. 
 
 
Fig. 5     
1
H NMR NOESY spectrum of 5 trans (CD2Cl2, 500 MHz, mixing time 800msec, 
224 K); resonance labelling follows Scheme 1. Black cross peaks indicate dynamic exchange 
peaks between conformers 
4
C1,N and 
1,N
C4, red cross peaks indicated inter-proton NOEs. Note 
the NOE between H6 and the NMe2 is not visible in the figure shown, but is present at higher 
contour levels, modelling suggests inter-proton distances >3.2 Å. 
 
 
 
Conclusions  
 
Overall, the conformational analyses reveal that the investigated caprolactams prefer to adopt 
a chair conformation featuring a planar arrangement of the lactam group (C2-C1-N1-C6). The 
positions of the attached substituents relative to the ring are summarized in Table 5. Bond 
lengths and torsion angles of the caprolactam ring differ only slightly with C2-, C6- or N-
substitution as shown by the X-ray data. Formation of amide ‘dimers’ were observed 
crystallographically in four of the six possible cases. The introduction of unsaturation, i.e. a 
C-2/C-3 alkene, has a considerable effect resulting in the seven membered ring chair 
conformation being partially flat along the -C1-C2=C3-C4- portion of the molecule. There is 
no residual solvent accessible void in any of the structures of the presented -caprolactams, 
which is promoted by weak C-H∙∙∙O contacts. Interestingly, in almost all structures, the 
slightly acidic proton at C-6 may be involved in these interactions. For the caprolactams 1, 5 
(cis) and 6 (cis), the –COOMe residue occupies an equatorial position, but is forced into the 
axial position by the introduction of a BOC group at a neighbouring atom (3) or by ring 
desaturation (7).  
 
The NMR studies are consistent with the chair conformations dominating in solution. 
Caprolactam 3 was found to undergo dynamic exchange between two chair forms, one with 
the ester equatorial (30 %) and the other with the ester axial (70 %), the latter observed in the 
X-ray structure. For the C2-substituted seven-membered rings 5 and 6, we observed one chair 
form for both cis isomers with both ester and and dithiocarbamate groups occupying 
equatorial positions. The respective trans isomers exist in equilibrium between two chair 
forms in an 1:1 ratio where either substituent can occupy axial or equatorial positions. In all 
cases, solvent e.g. benzene or chloroform had only negligible influence on the conformational 
properties of the caprolactams. 
 
 
Experimental section 
 
Materials and Methods 
 
All reactions involving moisture sensitive reagents were carried out under a nitrogen 
atmosphere. Cooling was performed in ice-water baths (0 °C) or dry ice-acetone baths (-78 
°C). Anhydrous solvents were obtained from solvent stills and were activated by passing over 
a short column of activated alumina. Reagents were obtained from Acros or Aldrich fine 
chemical suppliers and used as supplied. Thin layer chromatography (TLC) was performed on 
Merck DC-Kieselgel 60 F 254 0.2 mm precoated plates with fluorescence indicator. 
Visualization of spots was achieved using UV light (254 nm) and by developing in a basic 
solution of KMnO4 followed by heating. Chromatography was performed using a Biotage 
SP4 chromatography system, using prepacked Biotage KP-SIL SNAP columns.  
 
Proton nuclear magnetic resonance spectra (
1
H NMR) were recorded using a Bruker AV400 
(400 MHz) and AVII 500 (500 MHz) spectrometers. Proton decoupled carbon nuclear 
magnetic resonance spectra (
13
C NMR) were recorded on a Bruker AV400 (100 MHz) and 
AVII 500 (125.6 MHz) with sample temperatures regulated at 298K, unless otherwise stated. 
Spectra were assigned using COSY, DEPT-135, HMQC, edited-HSQC, and HMBC. All 
chemical shifts are quoted on the scale in ppm and referenced to residual solvent peaks; 
CD2Cl2 at 5.32 ppm and C6D6 at 7.2 ppm and calculated internally by the spectrometer. 
Resonances are described as s (singlet), d (doublet), t (triplet), m (multiplet), and br s (broad 
singlet). 1-D NOE experiments were performed using DPFGSE-NOE pulse sequence 
employing two 180 degree pulses and a mixing time of 800 msec.
39
 
 
Single crystals suitable for single crystal X-ray diffraction studies were obtained from 
cyclohexane for compound 1 and from a mixture of dichloromethane/methanol (1:1) for 5, 6 
and 7. Compound 3 was recovered as a colourless oil, that produced suitable crystals after 
some weeks. Single crystal X-ray diffraction data were collected using a Nonius Kappa CCD 
diffractometer (1) or Oxford Diffraction (Agilent) SuperNova diffractometer (2-7) fitted with 
an Oxford Cryosystems Cryostream open-flow nitrogen cooling device. Data collection and 
reduction were carried out using HKL COLLECT/DENZO-SCALEPACK
40
 or CrysAlisPro 
as appropriate. Structures were solved using SIR92
41
 within the CRYSTALS suite
42
 and 
optimized by full-matrix least squares on F
2
. Hydrogen atoms were not generally provided by 
the initial solution, however they were usually clearly visible in the difference Fourier map. 
Hydrogen atoms were positioned at geometrically sensible positions and refined using soft 
restraints prior to inclusion in the final refinement using a riding model.
43
 The rmsD and 
maxD data were calculated with the program Mercury
44
 and torsion angles were calculated 
using PLATON.
45
 CCDC numbers: 1018875-1018881. 
 
IR spectra were recorded using a Bruker Tensor 27 ATR-FT-IR spectrophotometer. Selected 
absorption maxima (νmax ) are given in wavenumbers (cm
-1
) and are uncorrected. Mass spectra 
were recorded on a Waters LCT premier. Melting points were recorded on a Leica VMTG 
heated-stage microscope melting point apparatus. 
 
All molecular modelling work was carried out using the Schrödinger’s Maestro modelling 
package employing MacroModel with the Schrödinger’s implementation of the OPLS_2005 
molecular mechanics force field.
46
 Conformational searches were performed as follows. 
Initial molecular models for each compound were energy minimised (convergence criterion: 
RMS energy gradient < 0.001 kcal/mol/Å) using constant dielectric constant with chloroform  
as the solvent and used as starting points for molecular dynamics simulations at an effective 
temperature of 1000 K. A total of 50 samples were extracted from each dynamics trajectory 
with a time interval of 1 ps between samples. The sampled structures were then energy 
minimised, and structural duplicates removed (match criterion: heavy atom RMSD < 0.2 Å). 
The final set of unique minimum-energy conformers was then sorted according to calculated 
energy. 
 
 
Syntheses 
 
Methyl 7-oxoazepane-2-carboxylate (1). Methanol (30 ml) was cooled to -10 °C and 
thionylchloride (2.5 ml, 34.46 mmol) was dropped in with stirring. Subsequently, (±)-2-
aminopimelic acid (3.0 g, 17.13 mmol) was added, the reaction mixture allowed to warm to 
room temperature and was stirred overnight. The solvents were removed in vacuo, to yield the 
hydrochloride of the amino acid, which was used without purification. The intermediate was 
neutralized by addition of a small amount of water containing sodium bicarbonate (1 eq.), 
before extracting this solution with ethyl acetate. The organic phase was dried (MgSO4), 
filtered and concentrated to afford the free base. After addition of p-cymene (80 ml), the 
mixture was stirred at reflux for 72 h. The solvent was removed under reduced pressure and 
the residue was purified by flash chromatography (SiO2; eluent: ethyl acetate). White solid. 
Yield: 1.68 g (57 %, 9.81 mmol). Mp. 75-76 °C. Rf = 0.35 (SiO2; ethyl acetate).  
13
C NMR (100 MHz, CDCl3):  = 176.2 (COOCH3), 171.9 (CONH) 55.7, 52.9 (COOCH3, 
NHCH), 37.0 (CH2), 33.7 (CH2), 29.5 (CH2), 23.0 (CH2). 
1
H NMR (400 MHz, CDCl3):  = 
6.45 (br s, 1H, NH), 4.07-4.03 (m, 1H, NHCH), 3.74 (s, 3H, COOCH3), 2.47-2.33 (m, 2H, 
CH2), 2.19-2.15 (m, 1H, CH2), 2.03-1.96 (m, 1H, CH2), 1.86-1.77 (m, 1H, CH2), 1.65-1.51 
(m, 3H, CH2). IR: 3270, 2949, 2919, 2865, 1740, 1645, 1557, 1513, 1468, 1437, 1404, 1343, 
1312, 1298, 1261, 1241, 1214, 1196, 1183, 1136, 1107, 1089, 1062, 1012, 965, 933, 873, 850, 
801, 733. m/z = 172.11 [M+H
+
], calc. 172.09 
 
7-Oxoazepane-2-carboxylic acid (2). Methyl 7-oxoazepane-2-carboxylate (1) (1.08 g, 6.33 
mmol) was dissolved in tetrahydrofuran (35 ml). Lithium hydroxide monohydrate (1.06 g, 
25.27 mmol) in water (50 ml) and 6.2 ml hydrogen peroxide solution (30%) were added and 
the solution stirred overnight. The pH of the aqueous layer was adjusted to three with 
hydrochloric acid (2M) and extracted three times with ethyl acetate. The organic layers were 
combined and washed with water (3 x) and with brine (1 x). The solution was dried (Na2SO4) 
and the solvent removed in vacuo to yield 693 mg (70 %, 4.41 mmol of a white solid. Mp. 
161-162 °C (Lit.
47
: 160-162 °C).  
13
C NMR (100 MHz, CD3OD):  = 178.9 (COOH), 173.8 (CONH), 55.9 (NHCH), 36.6 
(CH2), 33.4 (CH2), 29.2 (CH2), 23.1 (CH2). 
1
H NMR (400 MHz, CD3OD):  = 4.18-4.13 (m, 
1H, NHCH), 2.59-2.40 (m, 1H, CH2), 2.50-2.48 (m, 1H, CH2), 2.25-2.17 (m, 1H, CH2), 2.03-
1.96 (m, 1H, CH2), 1.89-1.81 (m, 1H, CH2), 1.78-1.67 (m, 1H, CH2). IR: 3234, 2922, 2850, 
1703, 1612, 1443, 1413, 1358, 1343, 1327, 1265, 1250, 1229, 1220, 1203, 1191, 1152, 1086, 
1026, 942, 878, 853, 834, 807, 755, 728. m/z = 156.07 [M-H
+
], calc. 156.17. 
 
1-tert-Butyl 2-methyl 7-oxoazepane-1,2-dicarboxylate (3). Under a nitrogen atmosphere 
methyl ester 1 (481 mg, 1.77 mmol) was dissolved in dry toluene (50 ml). Subsequently, 
Hunig’s base (603 µl, 3.54 mmol) and 4-(N,N-dimethylamino)pyridine (43 mg, 0.35 mmol) 
were added at room temperature. To this mixture, a solution of di(tert-butyl)dicarbonate (1.93 
g, 8.86 mmol) in dry toluene (10 ml) was added and the resulting mixture stirred overnight 
under reflux. After cooling down, water (40 ml) was added and the mixture stirred at room 
temperature for 30 min. The organic layer was separated and dried over Na2SO4. Evaporation 
of the solvent and column chromatography yielded the respective compound. The crude 
products were purified by column chromatography (SiO2; n-hexane/ethyl acetate = 1:1). 86 % 
(481 mg, 1.77 mmol) of a colourless oil, which slowly crystallizes. Mp. 48-49 °C. Rf = 0.80 
(SiO2; n-hexane/ethyl acetate = 1:1). 
 
13
C NMR (100 MHz, CDCl3):  = 175.3 (COOCH3), 170.9 (CONH), 153.3 (NCOO
t
Bu), 83.2 
(C(CH3)3), 56.5 (NHCH), 52.4 (COOCH3), 39.5 (CH2), 29.8 (CH2), 27.9 (C(CH3)3), 25.6 
(CH2), 22.6 (CH2). 
1
H NMR (400 MHz, CDCl3):  = 5.16-5.12 (m, 1H), 3.71 (s, 3H), 2.63-
2.58 (m, 1H, CH2), 2.46-2.40 (m, 1H, CH2), 2.36-2.29 (m, 1H, CH2), 1.79-1.73 (m, 3H, CH2), 
1.51-1.46 (m, 2H, CH2), 1.43 (s,  9H). IR: 2983, 2961, 2933, 2869, 1715, 1701, 1454, 1434, 
1380, 1368, 1295, 1285, 1251, 1235, 1204, 1144, 1127, 1083, 1050, 1022, 986, 956, 929, 912, 
875, 842, 819, 806, 779, 745, 727, 704. m/z = 272.17 [M+H
+
], calc. 272.14. 
 
Methyl 6-bromo-7-oxoazepane-2-carboxylate (4). Methyl 7-oxoazepane-2-carboxylate (1) 
(342 mg, 2.00 mmol) was dissolved in dry dichloromethane (15 ml) and cooled to 0 °C. PCl5 
(458 mg, 2.20 mmol) and I2 (9 mg, 0.034 mmol) were added. The reaction mixture was stirred 
for 15 min at 0 °C. Then, bromine (354 mg, 2.22 mmol) in dichloromethane (2 ml) was 
added, and the reaction was stirred at 0 °C for 4 h. The reaction was quenched by adding 
aqueous sodium sulfite solution and extracted several times with dichloromethane. The 
combined organic phases were dried (Na2SO4), and the solvent was evaporated to yield a dark 
a red oil, which was column chromatographed (SiO2, ethyl acetate). Flesh-coloured oil (357 
mg, 1.43 mmol, 71 % yield) as a mixture of cis and trans isomers, which were inseparable by 
chromatographic techniques. Rf = 0.70 (SiO2; ethyl acetate).  
13
C NMR (100 MHz, CDCl3):  = 171.7, 170.2, 54.5 (COOCH3), 53.2 (CHCOO), 51.1 
(CHBr), 33.5 (CH2), 30.0 (CH2), 24.3 (CH2). 
1
H NMR (400 MHz, CDCl3):  = 6.67 (br s, 1H, 
NH), 4.63 (m, 1H, CHBr), 4.55 (dd, 
3
J = 11.0 Hz, 
2
J = 3.5 Hz, 1H, NHCH), 3.79 (s, 3H, 
COOCH3), 2.38-2.31 (m, 1H), 2.24-2.12 (m, 1H, CH2), 2.09-1.91 (m, 3H, CH2), 1.57-1.46 
(m, 1H, CH2). IR: 3347, 2952, 2933, 1734, 1672, 1434, 1379, 1360, 1337, 1303, 1269, 1240, 
1223, 1177, 1147, 1107, 1076, 1061, 1011, 939. m/z = 250.02, 251.98 [M+H
+
], calc. 250.00, 
252.00. 
 
Preparation of dithiocarbamates 5 and 6. Methyl 6-bromo-7-oxoazepane-2-carboxylate (4) 
(mixture of diastereomeres) (1 eq.) was dissolved in dioxane (15 ml) and the mixture was 
heated to 60 °C. Subsequently, a solution of the respective sodium dithiocarbamate (1.2 eq.) 
dissolved in methanol (15 ml), is added dropwise. After stirring is continued at 60 °C for 90 
min, the solvent is removed under reduced pressure. The raw material was purified by column 
chromatography (SiO2; n-hexane/ethyl acetate = 1:1  ethyl acetate) to yield in both cases 
two separable diastereomers.   
 
Methyl 6-[(dimethylcarbamothioyl)thio]-7-oxoazepane-2-carboxylate (5). Yield 80 % (202 
mg, 0.70 mmol) as a mixture of 178 mg (88 %) cis and 24 mg (12 %) trans isomer.  
cis-Methyl 6-[(dimethylcarbamothioyl)thio]-7-oxoazepane-2-carboxylate (5 cis). Mp. 136-
137 °C. Rf = 0.70 (SiO2; ethyl acetate). 
13
C NMR (100 MHz, DMSO/CD3OD):  = 195.5, 
172.5, 171.2, 57.6, 55.5, 51.1, 45.3, 41.7, 33.6 (CH2), 32.3 (CH2), 24.3 (CH2). 
1
H NMR (400 
MHz, CDCl3):  = 6.60 (br s, 1H, NH), 4.96 (dd, 1H, CHSC=S), 4.35 (dd, 1H, NHCH), 3.80 
(s, 3H, COOCH3), 3.51, 3.39 (s, NCH3, 6H), 2.30-2.20 (m, 1H), 2.12-2.03 (m, 2H, CH2), 
1.96-1.84 (m, 2H, CH2), 1.59-1.49 (m, 1H, CH2). IR: 3369, 3308, 2950, 2859, 1738, 1654, 
1490, 1433, 1395, 1367, 1353, 1329, 1305, 1216, 1135, 1081, 1034, 1007, 983, 943, 873, 854, 
817, 786, 742, 718. m/z = 291.11 [M+H
+
], calc. 291.08. 
trans-Methyl 6-[(dimethylcarbamothioyl)thio]-7-oxoazepane-2-carboxylate (5 trans). Mp. 
111-113 °C. Rf = 0.65 (SiO2; ethyl acetate). 
1
H NMR (400 MHz, dichloromethane):  = 6.54 
(br s, 1H, NH), 5.07 (d, 1H, 
3
J = 8.0 Hz, CHSC=S), 4.59 (dd, 
3
J = 10 Hz, 
2
J = 4 Hz, 1H, 
NHCH), 3.89 (t, 
3
J = 10 Hz, NCH2CH2), 3.83 (s, 3H, COOCH3), 3.71 (t, 
3
J = 10 Hz, 
NCH2CH2), 2.45-2.37 (m, 1H), 2.33-2.21 (m, 1H, CH2), 2.14-2.07, 2.02-1.97 (m, NCH2CH2, 
4H), 1.93-1.84 (m, 3H, CH2), 1.61-1.54 (m, 1H, CH2). 
13
C NMR (100 MHz, DMSO/CD3OD): 
 = 195.1, 172.8, 171.3, 56.7, 54.7, 53.1, 45.7, 41.6, 33.0 (CH2), 32.5 (CH2), 25.2 (CH2). IR: 
3364, 3245, 3089, 3038, 2984, 2946, 2937. 1747, 1708, 1655, 1478, 1455,1440, 1408, 
1376,1363, 1348, 1325, 1307, 1288, 1274, 1250, 1205, 1177, 1157, 1126, 1105, 1084, 1030, 
1012, 984, 945, 896, 879, 869, 841, 800, 774. m/z = 291.11 [M+H
+
], calc. 291.08. 
 
Methyl 6-[(pyrrolidine-1-carbonothioyl)thio]-7-oxoazepane-2-carboxylate (6). Yield 77 % 
(296 mg, 0.94 mmol) of a mixture consisting of 213 mg (72 %) cis and 83 mg (28 %) trans 
isomer. 
cis-Methyl 6-[(pyrrolidine-1-carbonothioyl)thio]-7-oxoazepane-2-carboxylate (6 cis). Mp. 
129-131 °C. Rf = 0.70 (SiO2; ethyl acetate). 
1
H NMR (400 MHz, dichloromethane):  = 6.54 
(br s, 1H, NH), 5.07 (d, 1H, 
3
J = 8.0 Hz, CHSC=S), 4.59 (dd, 1H, NHCH), 3.89 (t, 
3
J = 10 Hz, 
NCH2CH2), 3.82 (s, 3H, COOCH3), 3.71 (t, 
3
J = 10 Hz, NCH2CH2), 2.45-2.37 (m, 1H), 2.33-
2.21 (m, 1H, CH2), 2.14-2.07, 2.02-1.97 (m, NCH2CH2, 4H), 1.93-1.84 (m, 3H, CH2), 1.61-
1.54 (m, 1H, CH2). 
13
C NMR (100 MHz, CDCl3):  = 191.0, 172.5, 171.6, 56.5, 55.2, 54.5, 
53.2, 51.1, 32.8 (CH2), 32.7 (CH2), 28.9 (CH2), 26.7 (CH2), 24.3 (CH2). IR: 3369, 3303, 2950, 
1736, 1657, 1431, 1396, 1353, 1307, 1221, 1161, 1083, 1066, 1035, 1008, 946, 873, 855, 821, 
787, 739, 716. m/z = 317.08 [M+H
+
], calc. 317.09. 
trans-Methyl 6-[(pyrrolidine-1-carbonothioyl)thio]-7-oxoazepane-2-carboxylate (5 trans). 
Mp. 119-121 °C. Rf = 0.59 (SiO2; ethyl acetate). 
13
C NMR (100 MHz, CDCl3):  = 189.8, 
173.4, 171.4, 55.4, 55.3, 54.2, 53.1, 50.7, 33.9 (CH2), 32.5 (CH2), 26.1 (CH2), 25.2 (CH2), 
24.2 (CH2). 
1
H NMR (400 MHz, dichloromethane):  = 6.60 (br s, 1H, NH), 5.15 (d, 1H, 
CHSC=S), 4.24 (m, 1H, NHCH), 3.88 (t, 
3
J = 10 Hz, NCH2CH2), 3.83, 3.82 (s, 3H, 
COOCH3), 3.68 (t, 
3
J = 10 Hz, NCH2CH2), 2.48-2.38 (m, 1H), 2.31-2.23 (m, 1H, CH2), 2.13-
1.99 (m, NCH2CH2, 4H), 1.93-1.84 (m, 3H, CH2), 1.63-1.55 (m, 1H, CH2). IR: 3304, 3213, 
3096, 2954, 2872, 1727, 1655, 1432, 1363, 1332, 1316, 1287, 1253, 1215, 1185, 1164, 1124, 
1106, 1081, 1031, 1002, 957, 945, 889, 868, 846, 822, 794, 774. m/z = 317.08 [M+H
+
], calc. 
317.09. 
 
 
Pyrrolysis of dithiocarbamates. A solution of the respective thiocarbamate (5 or 6, resp.) 
(mixture of diastereomeres) (1 eq.) in diphenylether (6.0 g) was heated to reflux for 10 h. The 
dark brown reaction mixture was allowed to cool to room temperature, then purified by 
column chromatography (SiO2, ethyl acetate  ethyl acetate/MeOH = 9:1). In both cases, the 
pyrrolysis of the respective dithiocarbamate yielded a mixture of two different desaturation 
products (7 and 8). Pyrrolysis of 5 yielded 32 % (66 mg, 0.39 mmol) of 7 and 33 % (67 mg 
0.40 mmol) of 8. Pyrrolysis of 6 yielded 30 % (10 mg, 0.059 mmol) of 7 and 27 % (9 mg, 
0.053 mmol) of 8.  
 
Methyl 7-oxo-2,3,4,7-tetrahydro-1H-azepine-2-carboxylate (2) (7). Mp. 101-102 °C. Rf = 
0.20 (SiO2; ethyl acetate).  
13
C NMR (100 MHz, CDCl3):  = 171.5 (COOCH3), 168.4 (CONH), 140.2 (COCH=C), 126.0 
(COCH=C), 53.8, 53.0 (COOCH3, NHCH), 32.5 (CH2), 28.7 (CH2). 
1
H NMR (400 MHz, 
CDCl3):  = 6.67 (br s, 1H, NH), 6.37-6.28 (m, 1H, COCH=CH), 5.94 (dd, 
3
J = 12.5 Hz, 
2
J = 
2 Hz, 1H, COCH=C), 4.51-3.98 (m, 1H), 3.81 (s, 3H), 2.58-2.47 (m, 2H, CH2), 2.37-2.43 (m, 
1H, CH2), 2.04-2.14 (m, 1H, CH2). IR: 3277, 3238, 3182, 3132, 3031, 2956, 2923, 1720, 
1667, 1619, 1487, 1435, 1390, 1368, 1351, 1331, 1279, 1243, 1216, 1197, 1183, 1146, 1085, 
1044, 1009, 989, 932, 913, 874, 862, 836, 816, 784, 731. m/z = 170.11 [M+H
+
], calc. 170.07. 
 
Methyl 7-oxo-2,3,6,7-tetrahydro-1H-azepine-2-carboxylate (3) (8). Mp. 155-156 °C. Rf = 
0.38 (SiO2; ethyl acetate).  
13
C NMR (100 MHz, CDCl3):  = 173.2 (COOCH3), 171.1 (CONH), 127.2, 120.5 (COCH=C, 
COCH=C), 53.1, 52.8 (COOCH3, NHCH), 35.4 (CH2), 33.8 (CH2). 
1
H NMR (400 MHz, 
CDCl3):  = 6.52 (br s, 1H), 5.60-5.49 (m, 2H), 4.61-4.54 (m, 1H), 3.80 (s, 3H), 3.52-3.36 (m, 
1H, CH2), 2.91-2.80 (m, 1H, CH2), 2.71-2.59 (m, 1H, CH2), 2.49-2.35 (m, 1H, CH2). IR: 
3284, 3028, 2953, 1735, 1647, 1550, 1436, 1365, 1296, 1266, 1225, 1204, 1158, 1064, 1030, 
998, 966, 931, 904, 860, 808, 743, 669, 610. m/z = 170.11 [M+H
+
], calc. 170.07. 
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